Background: Transcatheter aortic valve implantation (TAVI) is an established alternative to surgical aortic valve replacement with evolving indications We investigate the mid-term outcomes of patients undergoing TAVI for severe aortic stenosis (AS) in our region Method: Patients undergoing TAVI for severe AS in the Auckland Region between 2011 and 2016 were included Combined endpoints of major adverse cardiovascular events (MACE) of all-cause mortality, stroke and rehospitalisation for heart failure were analysed up to 3 years post-procedure Results: A total of 147 patients were included in this study The mean age at implantation was 80 4±6 9 years, 83 (56 5%) were male and the mean EuroSCORE II was 6 5±4 4% At 3 years, MACE occurred in 62 (42 2%) patients, at a mean of 12 4 months from TAVI for first event The rates of all-cause mortality, stroke and heart failure hospitalisation were 22 4%, 8 2% and 25 9% respectively during this period Predictors of 3-year MACE were atrial fibrillation (HR 2 1, 95% CI: 1 27-3 44), transapical access (HR 2 6, 95% CI 1 03-4 97) and at least moderate residual valvular or paravalvular regurgitation (HR 2 9, 95% CI 1 32-6 42) Patients who were re-hospitalised for heart failure were less likely to survive than those who were not (63 1% vs 82 6%, p=0 014) Of the 38 patients re-hospitalised for heart failure, 10 (26 3%) were re-hospitalised within 3 months of their TAVI Conclusion: A history of atrial fibrillation, transapical access and at least moderate residual regurgitation were predictors of mid-term MACE after TAVI Patient who were re-hospitalised for heart failure after TAVI were less likely to survive
Mid-Term Outcomes of Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis: The Auckland Region Experience 2011-2016